Cytos Biotechnology Ltd. is renamed Kuros Biosciences Ltd.

Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd.

21-Jan-2016 - Switzerland

Kuros Biosciences Ltd. announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all 508'432'244 Kuros Biosciences Ltd. shares are listed and freely tradable under the ticker symbol KURN on the SIX Swiss Exchange under the International Reporting Standard and include all former 108’015’276 Cytos Biotechnology AG shares, which remain listed and freely tradable under the unchanged ISIN number (CH0011025217).

Christian Itin, Chairman of Kuros Board of Directors, stated: “We are pleased with the successful closing of the business combination and welcome our new shareholders. Kuros’ product candidates address important markets in wound care and bone regeneration. We are excited about the potential to create long-term value for shareholders.”

Didier Cowling, CEO of Kuros, commented: “Kuros has a diversified and clinically tested product pipeline with significant revenue potential in attractive markets. This combination provides us with access to the public capital markets and thereby achieves a key step in Kuros’ development.”

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...